Volume 373, Issue 9660, Pages 301-308 (January 2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Anders Widmark, MD, Olbjørn Klepp, MD, Arne Solberg, MD, Jan-Erik Damber, MD, Anders Angelsen, MD, Per Fransson, PhD, Jo- Åsmund Lund, MD, Ilker Tasdemir, MD, Morten Hoyer, MD, Fredrik Wiklund, PhD, Sophie D Fosså, MD The Lancet Volume 373, Issue 9660, Pages 301-308 (January 2009) DOI: 10.1016/S0140-6736(08)61815-2 Copyright © 2009 Elsevier Ltd Terms and Conditions
Figure 1 Trial profile The Lancet 2009 373, 301-308DOI: (10.1016/S0140-6736(08)61815-2) Copyright © 2009 Elsevier Ltd Terms and Conditions
Figure 2 Cumulative incidence of (A) PSA recurrence, (B) death from prostate cancer, and (C) death from any cause The Lancet 2009 373, 301-308DOI: (10.1016/S0140-6736(08)61815-2) Copyright © 2009 Elsevier Ltd Terms and Conditions
Figure 3 Absolute risk reduction in 10-year cumulative incidence of prostate-cancer-specific mortality in the endocrine plus radiotherapy group as compared to the endocrine alone group stratified by T stage, diagnostic PSA level, and age at start of treatment The Lancet 2009 373, 301-308DOI: (10.1016/S0140-6736(08)61815-2) Copyright © 2009 Elsevier Ltd Terms and Conditions